Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Li

Showing results (131-140 of 206) with videos related to

Pageof 21
Sort By:
Urologic Oncology|August 24, 2021
Comparative effectiveness analysis of first-line immunotherapy versus chemotherapy in metastatic urothelial carcinoma of the bladderNicholas H Chakiryan, Da David Jiang, Kyle A Gillis, et al.
BJU International|November 19, 2020
The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-GuérinNathan A Brooks, Andrea Kokorovic, Lianchen Xiao, et al.
European Urology Focus|July 30, 2017
Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle InvasionMichael J Metcalfe, James E Ferguson, Roger Li, et al.
The Journal of Urology|January 9, 2026
Predictors and Patterns of Nonurothelial Recurrence After Nephroureterectomy for Upper Tract Urothelial Carcinoma (UCAN Collaboration): ErratumAndrew B Katims, Amy L Tin, Melissa Assel, et al.
European Urology Focus|December 20, 2025
Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder Cancer: Survival Benchmarks, Bladder-sparing Strategies, and Implications for Trial DesignSeyed Behzad Jazayeri, Renzo G DiNatale, Christopher Guske, et al.
European Urology Oncology|June 19, 2022
Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer GroupWei Shen Tan, Gary Steinberg, J Alfred Witjes, et al.
Urologic Oncology|December 25, 2024
The role of neoadjuvant systemic therapy for high grade upper tract urothelial carcinoma: Results from the upper tract collaborative network (UCAN)Gianpaolo P Carpinito, Thomas Gerald, Patrick J Hensley, et al.
Urologic Oncology|July 10, 2022
Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancerAhmet Murat Aydin, Salim K Cheriyan, Richard Reich, et al.
European Urology|March 8, 2020
Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-GuérinRoger Li, Debasish Sundi, Jingsong Zhang, et al.
BJU International|October 26, 2022
Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi-institutional retrospective cohort studyKyle M Rose, Gopal Narang, Geoffrey Rosen, et al.
Pageof 21

Showing results (131-140 of 206) with videos related to

Sort By:
Pageof 21
Urologic Oncology|August 24, 2021
Comparative effectiveness analysis of first-line immunotherapy versus chemotherapy in metastatic urothelial carcinoma of the bladderNicholas H Chakiryan, Da David Jiang, Kyle A Gillis, et al.
BJU International|November 19, 2020
The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-GuérinNathan A Brooks, Andrea Kokorovic, Lianchen Xiao, et al.
European Urology Focus|July 30, 2017
Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle InvasionMichael J Metcalfe, James E Ferguson, Roger Li, et al.
The Journal of Urology|January 9, 2026
Predictors and Patterns of Nonurothelial Recurrence After Nephroureterectomy for Upper Tract Urothelial Carcinoma (UCAN Collaboration): ErratumAndrew B Katims, Amy L Tin, Melissa Assel, et al.
European Urology Focus|December 20, 2025
Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder Cancer: Survival Benchmarks, Bladder-sparing Strategies, and Implications for Trial DesignSeyed Behzad Jazayeri, Renzo G DiNatale, Christopher Guske, et al.
European Urology Oncology|June 19, 2022
Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer GroupWei Shen Tan, Gary Steinberg, J Alfred Witjes, et al.
Urologic Oncology|December 25, 2024
The role of neoadjuvant systemic therapy for high grade upper tract urothelial carcinoma: Results from the upper tract collaborative network (UCAN)Gianpaolo P Carpinito, Thomas Gerald, Patrick J Hensley, et al.
Urologic Oncology|July 10, 2022
Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancerAhmet Murat Aydin, Salim K Cheriyan, Richard Reich, et al.
European Urology|March 8, 2020
Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-GuérinRoger Li, Debasish Sundi, Jingsong Zhang, et al.
BJU International|October 26, 2022
Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi-institutional retrospective cohort studyKyle M Rose, Gopal Narang, Geoffrey Rosen, et al.
Pageof 21